Director, Global Content Enablement Platforms
Alnylam Pharmaceuticals | |
paid time off
| |
United States, Massachusetts, Cambridge | |
675 West Kendall Street (Show on map) | |
Feb 14, 2026 | |
|
Overview: The Director,GlobalContent Enablement Platformsis responsible forbusiness ownership of Alnylam's web content platforms and for defining the standards, governance, and operatingmodelthat enable compliant, scalable digital publishing across global markets. This roleoperateswith aglobal-firstmindset. The Director designs publishing frameworks, governance standards, and workflows that can be executed consistently across regions, including markets with differing regulatory, language, and operational requirements. A critical aspect of the role is close partnership with the International Omnichannel Operations lead to ensure these standards are practical, executable, and scalable outside the United States. The Director, Content Enablement leads a team of content enablement leads and serves as the people manager with individuals based in the US andInternationally. Together, this team ensures consistent execution standards across markets while allowing forappropriate regionalvariation. Through 2026, the focus will be on stabilizing core platforms, standardizing publishing practices, reducing web risk, andestablishingthe foundation for modular content reuse. The role partners closely withIT'stechnical product owners, Marketing Operations, and external vendors, whileretainingclear boundaries around technical ownership, whichremainswith IT. Key Responsibilities:
Expected Partnerships & Interfaces:
Qualifications:
#LI-ST1 #LI-Hybrid U.S. Pay Range $195,500.00 - $264,500.00 The pay range reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on a number of factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus or sales incentive) and an annual long-term incentive award (e.g., equity). Alnylam's robust Total Rewards package is designed to support your overall health and well-being. We offer comprehensive benefits including medical, dental, and vision coverage, life and disability insurance, a lifestyle reimbursement program, flexible spending and health savings accounts and a 401(k)with a generous company match. Eligible employees enjoy paid time off, wellness days, holidays, and two company-wide recharge breaks. We also offer generous family resources and leave. Our commitment to your well-being reflects our belief that caring for our people fuels the impact we create together. Learn more about these and additional benefits offered by Alnylam by visiting the Benefits section of the Careers website: https://www.alnylam.com/careers AboutAlnylam We are the leader in RNAi therapeutics- a revolutionaryapproach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has delivered the breakthroughs that made RNAi therapeutics possibleand are just at the beginning of what's possible. Our deep pipeline, late-stage programs, and bold vision reflect our core values: fierce innovation, passion for excellence, purposeful urgency, open culture and commitment to people. We're proud to be a globally recognized top employer, wherean authentic, inclusive culture and breakthrough thinkingfuel one another. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. Qualified applicants will receive consideration for employment without regard to their sex, gender or gender identity, sexual orientation, race, color, ethnicity, national origin, ancestry, citizenship, religion, creed, physical or mental disability, pregnancy status or related conditions, genetic information, veteran or military status, marital or familial status, political affiliation, age, or any other factor protected by federal, state, or local law. Alnylam is an E-Verify Employer. > | |
paid time off
Feb 14, 2026